Hypercholesterolemia - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 236 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hypercholesterolemia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Hypercholesterolemia - Pipeline Review, H2 2015', provides an overview of the Hypercholesterolemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hypercholesterolemia Overview 9
Therapeutics Development 10
Pipeline Products for Hypercholesterolemia - Overview 10
Pipeline Products for Hypercholesterolemia - Comparative Analysis 11
Hypercholesterolemia - Therapeutics under Development by Companies 12
Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes 16
Hypercholesterolemia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Hypercholesterolemia - Products under Development by Companies 21
Hypercholesterolemia - Products under Investigation by Universities/Institutes 26
Hypercholesterolemia - Companies Involved in Therapeutics Development 27
3SBio Inc. 27
Abeome Corporation 28
Aegerion Pharmaceuticals, Inc. 29
Amgen Inc. 30
AtheroNova Inc. 31
BioLingus AG 32
Catabasis Pharmaceuticals, Inc. 33
Cerenis Therapeutics Holding SA 34
CymaBay Therapeutics, Inc. 35
Daewon Pharm Co. Ltd. 36
DreamPharma Corp. 37
Dybly AG 38
Eli Lilly and Company 39
Esperion Therapeutics, Inc. 40
F. Hoffmann-La Roche Ltd. 41
Gemphire Therapeutics Inc. 42
Hanmi Pharmaceuticals, Co. Ltd. 43
Immune Response BioPharma, Inc. 44
Johnson & Johnson 45
Kadmon Corporation, LLC 46
Kowa Company, Ltd. 47
Merck & Co., Inc. 48
Novartis AG 49
Pfizer Inc. 50
Regeneron Pharmaceuticals, Inc. 51
RegenxBio Inc. 52
Sanofi 53
Serometrix, LLC 54
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 55
The Medicines Company 56
Thetis Pharmaceuticals LLC 57
Viking Therapeutics, Inc. 58
Zhejiang Hisun Pharmaceutical Co., Ltd. 59
Hypercholesterolemia - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Target 62
Assessment by Mechanism of Action 65
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
(aspirin + lisinopril + lovastatin) - Drug Profile 72
(atorvastatin calcium + TP-452) - Drug Profile 73
(bempedoic acid + ezetimibe) - Drug Profile 74
(ezetimibe + atorvastatin calcium) - Drug Profile 75
(ezetimibe + rosuvastatin calcium) - Drug Profile 76
AEM-28 - Drug Profile 77
AEM-2802 - Drug Profile 78
AEM-2814 - Drug Profile 79
AHRO-001 - Drug Profile 80
alirocumab - Drug Profile 82
ALN-PCSsc - Drug Profile 86
AM-0010 - Drug Profile 87
anacetrapib - Drug Profile 89
Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases - Drug Profile 91
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile 92
aplexone - Drug Profile 93
bempedoic acid - Drug Profile 94
bococizumab - Drug Profile 96
BSN-272 - Drug Profile 97
CAT-2000 Series - Drug Profile 98
CAT-2003 - Drug Profile 99
CAT-2054 - Drug Profile 100
CER-001 - Drug Profile 101
colestilan chloride - Drug Profile 103
Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 104
DW-0929 - Drug Profile 105
DW-3102 - Drug Profile 106
DYB-186 - Drug Profile 107
EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 108
EP-80317 - Drug Profile 110
evinacumab - Drug Profile 111
evolocumab - Drug Profile 112
fenofibrate - Drug Profile 115
gemcabene calcium - Drug Profile 117
Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 118
HCP-1305 - Drug Profile 119
HGP-0816 - Drug Profile 120
HS-25 - Drug Profile 121
IR-1002 - Drug Profile 122
ISIS-APOCIIILRx - Drug Profile 123
J-17 - Drug Profile 124
KD-026 - Drug Profile 125
lomitapide mesylate - Drug Profile 127
LY-3015014 - Drug Profile 130
MBX-8025 - Drug Profile 131
MGL-3196 - Drug Profile 133
mipomersen sodium - Drug Profile 135
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 137
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 138
PCSK-9 - Drug Profile 139
PF-06678552 - Drug Profile 140
pitavastatin CR - Drug Profile 141
pradigastat sodium - Drug Profile 142
RGX-501 - Drug Profile 143
Small Molecule for Hypercholesterolemia - Drug Profile 144
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile 145
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 146
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 147
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 148
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 150
ST-101 - Drug Profile 151
SX-PCK9 - Drug Profile 152
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 153
TP-452 - Drug Profile 154
VK-0214 - Drug Profile 155
VK-2809 - Drug Profile 156
volanesorsen sodium - Drug Profile 158
Hypercholesterolemia - Recent Pipeline Updates 160
Hypercholesterolemia - Dormant Projects 214
Hypercholesterolemia - Discontinued Products 219
Hypercholesterolemia - Product Development Milestones 221
Featured News & Press Releases 221
Appendix 230
Methodology 230
Coverage 230
Secondary Research 230
Primary Research 230
Expert Panel Validation 230
Contact Us 230
Disclaimer 231

List of Tables

Number of Products under Development for Hypercholesterolemia, H2 2015 15
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 18
Number of Products under Development by Companies, H2 2015 (Contd..1) 19
Number of Products under Development by Companies, H2 2015 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2015 21
Comparative Analysis by Late Stage Development, H2 2015 22
Comparative Analysis by Clinical Stage Development, H2 2015 23
Comparative Analysis by Early Stage Development, H2 2015 24
Comparative Analysis by Unknown Stage Development, H2 2015 25
Products under Development by Companies, H2 2015 26
Products under Development by Companies, H2 2015 (Contd..1) 27
Products under Development by Companies, H2 2015 (Contd..2) 28
Products under Development by Companies, H2 2015 (Contd..3) 29
Products under Development by Companies, H2 2015 (Contd..4) 30
Products under Investigation by Universities/Institutes, H2 2015 31
Hypercholesterolemia - Pipeline by 3SBio Inc., H2 2015 32
Hypercholesterolemia - Pipeline by Abeome Corporation, H2 2015 33
Hypercholesterolemia - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2015 34
Hypercholesterolemia - Pipeline by Amgen Inc., H2 2015 35
Hypercholesterolemia - Pipeline by AtheroNova Inc., H2 2015 36
Hypercholesterolemia - Pipeline by BioLingus AG, H2 2015 37
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015 38
Hypercholesterolemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2015 39
Hypercholesterolemia - Pipeline by CymaBay Therapeutics, Inc., H2 2015 40
Hypercholesterolemia - Pipeline by Daewon Pharm Co. Ltd., H2 2015 41
Hypercholesterolemia - Pipeline by DreamPharma Corp., H2 2015 42
Hypercholesterolemia - Pipeline by Dybly AG, H2 2015 43
Hypercholesterolemia - Pipeline by Eli Lilly and Company, H2 2015 44
Hypercholesterolemia - Pipeline by Esperion Therapeutics, Inc., H2 2015 45
Hypercholesterolemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 46
Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc., H2 2015 47
Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 48
Hypercholesterolemia - Pipeline by Immune Response BioPharma, Inc., H2 2015 49
Hypercholesterolemia - Pipeline by Johnson & Johnson, H2 2015 50
Hypercholesterolemia - Pipeline by Kadmon Corporation, LLC, H2 2015 51
Hypercholesterolemia - Pipeline by Kowa Company, Ltd., H2 2015 52
Hypercholesterolemia - Pipeline by Merck & Co., Inc., H2 2015 53
Hypercholesterolemia - Pipeline by Novartis AG, H2 2015 54
Hypercholesterolemia - Pipeline by Pfizer Inc., H2 2015 55
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 56
Hypercholesterolemia - Pipeline by RegenxBio Inc., H2 2015 57
Hypercholesterolemia - Pipeline by Sanofi, H2 2015 58
Hypercholesterolemia - Pipeline by Serometrix, LLC, H2 2015 59
Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 60
Hypercholesterolemia - Pipeline by The Medicines Company, H2 2015 61
Hypercholesterolemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2015 62
Hypercholesterolemia - Pipeline by Viking Therapeutics, Inc., H2 2015 63
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2015 64
Assessment by Monotherapy Products, H2 2015 65
Assessment by Combination Products, H2 2015 66
Number of Products by Stage and Target, H2 2015 68
Number of Products by Stage and Mechanism of Action, H2 2015 71
Number of Products by Stage and Route of Administration, H2 2015 74
Number of Products by Stage and Molecule Type, H2 2015 76
Hypercholesterolemia Therapeutics - Recent Pipeline Updates, H2 2015 165
Hypercholesterolemia - Dormant Projects, H2 2015 219
Hypercholesterolemia - Dormant Projects (Contd..1), H2 2015 220
Hypercholesterolemia - Dormant Projects (Contd..2), H2 2015 221
Hypercholesterolemia - Dormant Projects (Contd..3), H2 2015 222
Hypercholesterolemia - Dormant Projects (Contd..4), H2 2015 223
Hypercholesterolemia - Discontinued Products, H2 2015 224
Hypercholesterolemia - Discontinued Products (Contd..1), H2 2015 225